Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPL-2009-0031
- Development stage
- Phase 3
- Lead developer
- Cadila Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CPL-2009-0031 is a small molecule inhibitor of dipeptidyl peptidase 4 (DPP4, also known as CD26 antigen), developed for the treatment of type 2 diabetes mellitus. It belongs to the chemical classes of amides, fluorobenzenes, piperazines, and triazoles. The drug acts by inhibiting DPP4, an enzyme that degrades incretin hormones such as GLP-1; this inhibition increases endogenous incretin levels and thereby enhances insulin secretion in response to meals while reducing glucagon secretion. CPL-2009-0031 is being developed by Cadila Pharmaceuticals and has reached phase III clinical trials in India for type 2 diabetes mellitus[1][2][5].
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on CPL-2009-0031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPL-2009-0031.